Koers Aphria Inc Toronto S.E.
Aandelen
APH
CA03765K1049
Farmaceutische producten
Omzet 2024 * | 783 mln. 1,07 mld. 727 mln. | Omzet 2025 * | 864 mln. 1,18 mld. 802 mln. | Marktkapitalisatie | 1,56 mld. 2,13 mld. 1,44 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -226 mln. -309 mln. -210 mln. | Nettowinst (verlies) 2025 * | -85 mln. -116 mln. -78,93 mln. | EV/omzet 2024 * | 2,22 x |
Nettoschuld 2024 * | 178 mln. 243 mln. 165 mln. | Nettoschuld 2025 * | 108 mln. 148 mln. 101 mln. | EV/omzet 2025 * | 1,93 x |
K/w-verhouding 2024 * |
-5,87
x | K/w-verhouding 2025 * |
-13,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,73% |
Recentste transcriptie over Aphria Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
Carl Merton
DFI | Director of Finance/CFO | - | 30-04-21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
David Clanachan
BRD | Director/Board Member | 62 | 30-04-21 |
Walter Robb
BRD | Director/Board Member | 70 | 30-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |